XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.23.1

Sale of Nonfinancial Assets | 3 Months Ended
--- | ---
Mar. 31, 2023
Sale of Nonfinancial Assets [Abstract] |
Sale of Nonfinancial Assets | 12. Sale of Nonfinancial Assets Asset Purchase Agreement with Sentynl On March 4, 2022, Origin and Sentynl entered into the Origin-Sentynl APA, pursuant to which Sentynl acquired global rights to NULIBRY TM, as well as certain specified assets of Origin, and will be responsible for the ongoing development and commercialization of NULIBRY TM in the United States and developing, manufacturing and commercializing fosdenopterin globally. The transaction closed on March 31, 2022, or the Closing Date. Under terms of the Origin-Sentynl APA, Origin received an upfront payment of $10.0 million upon the Closing Date and is eligible to receive sales milestone payments, as well as tiered royalties in the low single-digits as a percentage of adjusted net sales of products related to the acquired assets. Origin will continue to be responsible for the payment of up to $4.5 million in aggregate payments upon achievement of regulatory-based milestones under the Origin-Alexion APA (see Note 7). In October 2022, we paid $3.5 million of the regulatory-based milestone payment as the initial milestone criteria was met. As of March 31, 2023, Origin will continue to be responsible for a regulatory-based milestone payment upon first pricing approval in a European Medicines Agency, or EMA, country of up to $1.0 million when it becomes due. We accounted for this transaction under ASC 610-20. Upon the Closing Date, we recognized a loss on sale of $6.3 million within “Other expense, net” in our condensed consolidated statement of operations for the three months ended March 31, 2022. The loss on sale was determined as the difference in the aforementioned upfront payment and the carrying value of the assets purchased by Sentynl of approximately $16.3 million, which comprised mainly of intellectual property rights and related intangible assets and existing inventories as of the Closing Date. Origin’s sale of the assets covered in the Origin-Sentynl APA was not subject to the limitation on our ability to dispose of assets under the terms of the Amended Loan Agreeme nt (see Note 9).

X
- Definition Sale of Nonfinancial Assets. + References No definition available. + Details
Name: | bbio_SaleOfNonfinancialAssetsAbstract
Namespace Prefix: | bbio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sale of Nonfinancial Assets. + References No definition available. + Details
Name: | bbio_SaleOfNonfinancialAssetsTextBlock
Namespace Prefix: | bbio_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration